" class="no-js "lang="en-US"> EverImmune - Medtech Alert
Friday, September 26, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
EverImmune | Pharmtech Focus

EverImmune

About EverImmune

EverImmune

EverImmune is a spin-off biotech. Cie from Gustave Roussy Transfer ,Villejuif, France devoted to treating cancer with live biotherapeutic products (LBP) i.e immunogenic commensals that we call “Oncobax®”, for oral adjuvants to anticancer treatments.

Related Story

Fundraising

 EverImmune Raises €5M to Enter Clinical Phase in Microbiota Immuno-oncology | Pharmtech Focus

EverImmune Raises €5M to Enter Clinical Phase in Microbiota Immuno-oncology

November 30 2021

EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field […]